1. HER2 targeted breast cancer treatment has significantly improved prognosis. 2. Novel immune checkpoint therapies have resulted in considerable clinical response for a variety of cancer types. Evidence Rating Level: 2 (Good) Study Rundown: Cancer therapy is a continually evolving field, as researchers strive to determine the most effective methods of treating this complex disease.
Researchers assessed the use of cfDNA-based liquid biopsy to guide and expedite clinical trial enrollment for patients with with metastatic urothelial carcinoma.
Retrospective study examines the association between risk of cardiotoxicity and race in women with breast cancer receiving chemotherapy and at least 1 year of HER2-targeted therapy.
[OncoTargets and Therapy] This research reviews available data on the role of the HER2 pathway in breast cancer and on the different targeted agents for the treatment of patients with early-stage HER2-positive disease, with a particular focus on neratinib.
CDK4/6 inhibitors, which block the activity of regulatory enzymes, are tolerated fairly well in patients with cancer; however, oncology nurses should be aware of some strategies that minimize their adverse effects.
In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.
A male patient with a history of polycythemia vera that converted to myelofibrosis becomes a first known case of dermatomyositis associated with secondary myelofibrosis.
Phase 3 clinical trial results show fewer adverse effects and longer survival with alectinib compared with crizotinib in patients with treatment-naïve ALK-positive NSCLC.
Spherical Shape of New Drug Holds Promise for Bypassing the Blood Brain Barrier and Treating Aggressive Brain CancerJune 01, 2017
An investigational drug with a novel spherical nucleic acid structure has the potential to cross the blood-brain barrier to treat glioblastoma multiforme.
A combination treatment of mitogen-activated protein kinase MEK inhibitor and chemotherapy did not improve progression-free survival in patients with advanced lung cancer caused by a KRAS gene mutation.
A potential treatment targeting neutrophils holds promise for limiting kidney damage and improving renal function in cancer.
Progression-free survival rates are higher in patients treated with targeted therapies based on results of multigene panel tests.
Genetic signatures similar to BRCA1/BRCA2 mutations could make PARP inhibition a treatment option for some breast cancers.
Rosiglitazone has potential for older patients with melanoma who develop resistance to targeted therapies.
A new tool may enable oncologists to deliver radiation therapy targeted to a tumor's biology and radiosensitivity, similar to how anticancer agents target specific tumor mutation-affected gene pathways.
A new targeted therapy approach may attack cancer on two fronts, boosting anti-tumor immune responses while also directly killing tumor cells .
Atlhough survival for patients with advanced melanoma is similar with both targeted therapies and immunotherapies, a review of the literature reveals why one of them may be a better choice as first-line therapy.
Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of TrastuzumabAugust 03, 2016
Therapies targeting ErbB2 (HER2), such as trastuzumab (Herceptin), are often associated with cardiovascular side effects. ErbB2 was recently found to also be expressed by vascular endothelial cells, and is an example of how tissue growth and blood vessel patterning are integrated at the molecular level.
Preliminary results of a prospective, phase II trial show that once-daily accelerated partial breast irradiation (APBI) effectively prevented recurrence of cancer in the treated breast at a median 34 months after treatment.
Genetic mutations affecting the immune system were identified in patients who develop more than one CRC tumor at the same time, and understanding how these cancers develop could improve therapy targeting.
Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only approximately 3 in 10 such patients undergo the procedure.
Laser heat may soon be an option to treat prostate cancer. Focal laser ablation has been found both feasible and safe in men with intermediate risk prostate cancer.
Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).
Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.
Outcomes in Clinical Trials Using Precision Medicine Demonstrate Effectiveness of Modality in Patients With CancerJune 20, 2016
A meta-analysis of hundreds of cancer clinical trials revealed that therapeutic approaches using precision medicine had improved responses and longer disease remission, even in phase I trials.
Castration-resistant prostate cancer (CRPC) has specific metabolic characteristics that could make it susceptible to new options for treatment.
The FLT3 tyrosine kinase is the most frequent mutation found in AML, and targeting CDK6 with palbociclib may be an effective strategy against AML.
The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.
The genetically engineered epothilone analog, utidelone, in combination with capecitabine significantly improved progression-free survival and objective response rates in patients with metastatic breast cancer who were heavily pretreated, compared with capecitabine alone, results of a phase 3 trial presented at the 2016 ASCO Annual Meeting have shown.
The largest database on outcomes with RET-directed therapy for RET-rearranged NSCLC to date confirms RET inhibitors are active in a proportion of patients, a study presented at the 2016 ASCO Annual Meeting has shown.
Sign Up for Free e-newsletters
- Aggressive EOL Care Negatively Impacts Care Quality, Health Costs in Metastatic Lung Cancer
- Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype
- Myelofibrosis: From Diagnosis to Early Intervention
- HPV Vaccination and Anti-programmed Cell Death 1 Inhibition Improve Survival in Patients With Invasive HPV-16
- FDA Approves HPV Vaccine for People Through Age 45
- Anxiety, Depression in Prostate Cancer: Managing Psychosocial Effects in Male Patients
- Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma
- Tool Addresses Well-being of Informal Caregivers of Patients With Cancer
- Hematologic Cancers: 8 Tips Oncology Nurses Should Share with Caregivers
- Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment
- Should Increased Breast Density Dictate More Breast Cancer Screenings?
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Prisoner or Patient? Challenges of Cancer Care in the Incarcerated Population
- Eighth AJCC TNM Staging Equalizes Distribution, Improves Prognostics of Pancreatic Cancer Stages
- Smoking Ups Risk of Myeloproliferative Neoplasms Overall and by Subtype
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|